Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease
- PMID: 1350491
- DOI: 10.1007/BF00207618
Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease
Abstract
In a randomized, double-blind study oral doses of 50 mg carvedilol (Dilatrend) were compared with 40 mg propranolol in 16 male patients with coronary heart disease, CHD [12 without significant stenoses following percutaneous transluminal coronary angioplasty (PTCA), 4 with multivessel disease]. Bicycle ergometry in the supine position was performed before and 80 min after drug application; measurements were done at rest, during and after exercise. Clinically, the total exercise time and the onset of angina and exhaustion were noted, while the investigated hemodynamic parameters were heart rate, systemic and pulmonary pressures and resistances, cardiac index, and lower limb blood flow. Clinically, carvedilol improved the exercise tolerance more than propranolol as regards angina and exhaustion. Hemodynamically, carvedilol did not lead, as the classic betablocker propranolol does, to an increase in systemic or pulmonary resistance, to a decrease in cardiac output, or to an increase of the pulmonary capillary wedge pressure during exercise, but instead caused opposite changes. In contrast to propranolol, the post exercise lower limb blood flow had increased significantly. The differences in action between the two betablockers can be explained by the vasodilating properties of carvedilol. Due to these acute effects, carvedilol may be preferred to propranolol in the treatment of CHD patients with hypertension, peripheral occlusive artery disease, and/or coronary vasospasm.
Similar articles
-
Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol.J Cardiovasc Pharmacol. 1987;10 Suppl 11:S147-50. J Cardiovasc Pharmacol. 1987. PMID: 2454362 Clinical Trial.
-
[Acute hemodynamic effects of the vasodilator beta blocker carvedilol in heart failure].Z Kardiol. 1990 Jun;79(6):424-8. Z Kardiol. 1990. PMID: 1974100 Clinical Trial. German.
-
Long-term hemodynamic effects of antihypertensive treatment.Clin Investig. 1992;70 Suppl 1:S58-64. doi: 10.1007/BF00207613. Clin Investig. 1992. PMID: 1350486
-
Vasodilatory action of carvedilol.J Cardiovasc Pharmacol. 1992;19 Suppl 1:S5-11. doi: 10.1097/00005344-199219001-00003. J Cardiovasc Pharmacol. 1992. PMID: 1378150 Review.
-
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.Cardiovasc Drugs Ther. 1997 May;11 Suppl 1:247-56. doi: 10.1023/a:1007735729121. Cardiovasc Drugs Ther. 1997. PMID: 9211017 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical